Eppendorf, a leading life science company that develops and sells instruments, consumables and services for liquid, sample and cell handling in laboratories worldwide, invests in BigOmics Analytics, a Swiss biodata analytics startup. The additional funding brings the total amount raised so far to CHF 2.7 million.
The strategic investment was initiated and carried out by the Eppendorf Innovation Company (EpIC), which serves as Eppendorf’s interface for innovative startups. Upon signing the agreement, Peter Fruhstorfer, Co-CEO of Eppendorf SE, commented: “We’re excited to invest in BigOmics, with its expertise and digital know-how, the company is a perfect fit for Eppendorf and our ambition to improve work processes in the lab and set them up for the future.”
“BigOmics complements Eppendorf’s digital platform approach. With our VizioNize Lab Suite, we give researchers an efficient digital solution for managing their labs and conducting their experiments. The BigOmics portfolio complements our solution by smart analysis of the experimental data.” added Jochen Müller-Ibeler, Head of New Business Development at EpIC.
BigOmics’ vision is to fast-track omics data analysis and significantly reduce discovery time and R&D overhead costs in the field of data-driven therapeutics and precision medicine. Its governed self-service analytics platforms enable biologists and bioinformaticians to communicate interactively instead of exchanging static reports. With these platforms, bioinformaticians can delegate part of their routine work to biologists and let them analyze and interpret their data efficiently through an easy-to-use interface, thus allowing bioinformaticians to focus on more bespoke analyses. It represents a win-win proposition for both biologists and bioinformaticians and balances data quality and analysis agility.
To date, BigOmics has closed six enterprise subscriptions with Biotech/Pharma companies and academic labs. In December the company announced a $1.85 million financing round. The funds will be used to further develop BigOmics’ platforms, to expand its team and to grow its presence in the market.
(Press release / SK)
Photo L-R: Murodzhon Akhmedov (BigOmics Co-Founder and CEO), Jochen Müller-Ibeler (Head of New Business Development at EpIC) and Ivo Kwee (BigOmics Co-Founder and CTO).
Please login or sign up to comment.
Commenting guidelines